HER2: a 'predictive factor' ready to use in the daily management of breast cancer patients?

被引：47

作者：

Piccart, MJ ^{[1
]}

Di Leo, A ^{[1
]}

Hamilton, A ^{[1
]}

机构：

[1] Inst Jules Bordet, Unite Chimiotherapie, B-1000 Brussels, Belgium

来源：

EUROPEAN JOURNAL OF CANCER | 2000年 / 36卷 / 14期

关键词：

breast cancer; HER2/receptor tyrosine kinase; chemotherapy; hormonal therapy; prediction of response;

D O I：

10.1016/S0959-8049(00)00162-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The past few years have witnessed an exponential increase in studies trying to identify molecular markers in patients with breast rumours that might predict for the success or failure of hormonal therapy or chemotherapy. HER2, a tyrosine kinase membrane receptor of the epidermal growth factor receptor family. has been the most widely studied marker in this respect. This paper attempts to critically review to what extent HER2 may improve 'treatment individualisation' for the breast cancer patient, (C) 2000 Published by Elsevier Science Ltd.

引用

页码：1755 / 1761

页数：7

共 23 条

[1] HER-2/NEU IN NODE-NEGATIVE BREAST-CANCER - PROGNOSTIC-SIGNIFICANCE OF OVEREXPRESSION INFLUENCED BY THE PRESENCE OF INSITU CARCINOMA
ALLRED, DC
CLARK, GM
TANDON, AK
MOLINA, R
TORMEY, DC
OSBORNE, CK
GILCHRIST, KW
MANSOUR, EG
ABELOFF, M
EUDEY, L
MCGUIRE, WL
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) : 599 - 605
[2] [Anonymous], P AM SOC CLIN ONCOL
[3] EXPRESSION OF RAS P21, P53 AND C-ERBB-2 IN ADVANCED BREAST-CANCER AND RESPONSE TO FIRST LINE HORMONAL-THERAPY
ARCHER, SG
ELIOPOULOS, A
SPANDIDOS, D
BARNES, D
ELLIS, IO
BLAMEY, RW
NICHOLSON, RI
ROBERTSON, JFR
[J]. BRITISH JOURNAL OF CANCER, 1995, 72 (05) : 1259 - 1266
[4] Baselga J, 1997, Oncology (Williston Park), V11, P43
[5] BIANCO AR, 1998, P AN M AM SOC CLIN, V17, P97
[6] ERBB2 AMPLIFICATION IS ASSOCIATED WITH TAMOXIFEN RESISTANCE IN STEROID-RECEPTOR POSITIVE BREAST-CANCER
BORG, A
BALDETORP, B
FERNO, M
KILLANDER, D
OLSSON, H
RYDEN, S
SIGURDSSON, H
[J]. CANCER LETTERS, 1994, 81 (02) : 137 - 144
[7] p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer
Clahsen, PC
van de Velde, CJH
Duval, C
Pallud, C
Mandard, AM
Delobelle-Deroide, A
van den Broek, L
Sahmoud, TM
van de Vijver, MJ
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) : 470 - 479
[8] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
Cobleigh, MA
Vogel, CL
Tripathy, D
Robert, NJ
Scholl, S
Fehrenbacher, L
Wolter, JM
Paton, V
Shak, S
Lieberman, G
Slamon, DJ
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) : 2639 - 2648
[9] DILEO A, 1999, P AN M AM SOC CLIN, V18, pA69
[10] Elledge RM, 1998, CLIN CANCER RES, V4, P7

← 1 2 3 →